Share on facebook
Share on twitter
Share on linkedin
Share on telegram
Share on whatsapp

Gene Therapy: Moderna Announced “promising data” on mRNA Flu Vaccine

Share on facebook
Share on twitter
Share on telegram
Share on email
Share on print

Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed

Phase 2 dose-confirmation study was fully enrolled in November (N=500); preparation for Phase 3 study underway

Seasonal flu program now moving beyond quadrivalent: announcing mRNA-1011 & mRNA-1012 development candidates

View Phase 1 Study


Yahoo News – US biotech company Moderna on Friday announced promising data from an early-stage human trial of its mRNA flu shot, based on the same technology used in its Covid-19 vaccine.

The experimental flu shot was found to be safe, and successfully evoked high levels of antibodies in 180 people at all dosage levels, in both younger and older adults.

“Even before the Covid-19 pandemic, approximately three million people died each year due to respiratory infections, and many more are hospitalized or become ill as a result of these viruses,” said Moderna CEO Stephane Bancel in a statement hailing the result.

Side effects were mild, and occurred more often in younger than older adults. The most common included pain and tenderness at the injection site, as well as headaches, muscle and joint aches, and tiredness.

The next stage of the trial, involving 500 people, began last month, and aims to firm up the right dosage level and compare the Moderna flu vaccine to already-licensed shots developed using more traditional methods. Interim results are expected in early 2022. Read More

Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x

Get in Touch!

Purpose of your Contact
Where can i reach you?
What would you like to discuss?

Are you intending to visit the Lorphic marketing agency?